Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study.
Anne Hansen ReeGunhild M MælandsmoNorman John CarrHege G RussnesMónica Gómez CastañedaEline AasPublished in: Acta oncologica (Stockholm, Sweden) (2022)
NCT02142036.
Keyphrases